摘要
目的通过对急性淋巴细胞白血病患儿采用甲氨喋呤结合亚叶酸钙(HD-MTX-CF)化疗方案中血药浓度结果的分析,探讨甲氨蝶呤(MTX)血药浓度监测的临床意义,同时考察MTX排泄的个体差异性。方法采用HPLC法监测接受HD-MTX化疗的49例急性淋巴细胞白血病患儿的血药浓度,并应用SPSS13.0软件分析监测结果。结果自HD-MTX开始给药后48、72h,MTX血药浓度的变异系数较大;72h与48h血药浓度对数值呈正相关;MTX血药浓度监测提示:49例患儿的预期抗白血病作用较好,但MTX排泄延迟的现象发生次数较多。结论MTX的末端消除过程存在极大的个体差异性,HD-MTX-CF化疗过程需要在血药浓度监测下实施。给药后48h点的血药浓度对于后期排泄情况有一定的预见性,值得重视。
OBJECTIVE To approach the clinical significance of monitoring the serum concentration of methotrexate (MTX) in high does methotrexate combine calcium folinate (HD-MTX-CF) chemotherapy scheme for children with acute lymphoblastic leukemia,as well as to inspect the individual difference of methotrexate’s elimination.METHODS Using high performance liquid chromatography with solid phase extraction (Spe-HPLC) to monitor MTX serum concentration in 49 children with acute lymphoblastic leukemia who received high-do...
出处
《华西药学杂志》
CAS
CSCD
北大核心
2010年第2期219-221,共3页
West China Journal of Pharmaceutical Sciences
关键词
急性淋巴细胞白血病
甲氨蝶呤
亚叶酸钙
血药浓度监测
排泄
个体差异
Acute lymphoblastic leukemia
Methotrexate
Calcium folinate
Serum concentration monitoring
Elimination
Individual difference
